COEPW
Income statement / Annual
Last year (2024), Coeptis Therapeutics Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Coeptis Therapeutics Holdings, Inc.'s net income was -$9.81 M.
See Coeptis Therapeutics Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$75,000.00 |
$30,761.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.00 M
|
$1.00 M
|
$447,413.00
|
$964,217.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$1.00 M
|
-$1.00 M
|
-$372,413.00
|
-$933,456.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
-4.97
|
-30.35
|
0
|
| Research and Development Expenses |
$2.33 M
|
$6.67 M
|
$20,887.00
|
$0.00
|
$3,543.00
|
$0.00
|
| General & Administrative Expenses |
$945,641.00
|
$3.95 M
|
$34.17 M
|
$14.12 M
|
$5.77 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$12,710.00
|
$8,331.00
|
$2,918.00
|
$6,608.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$945,641.00
|
$13.82 M
|
$34.18 M
|
$14.12 M
|
$5.78 M
|
$0.00
|
| Other Expenses |
$6.78 M
|
$0.00
|
$233,701.00
|
$785,786.00
|
-$2.29 M
|
$0.00
|
| Operating Expenses |
$10.05 M
|
$20.49 M
|
$34.20 M
|
$14.12 M
|
$5.78 M
|
$0.00
|
| Cost And Expenses |
$0.00
|
$21.49 M
|
$34.20 M
|
$14.12 M
|
$6.74 M
|
$0.00
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1,204.00
|
$0.00
|
| Interest Expense |
-$396,116.00
|
-$107,685.00
|
$218,412.00
|
$187,133.00
|
$148,192.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.00 M
|
$1.00 M
|
$447,413.00
|
$323,428.00
|
$171,860.00
|
| EBITDA |
-$10.05 M |
-$20.16 M |
-$36.35 M |
-$12.81 M |
-$8.68 M |
$171,860.00 |
| EBITDA Ratio |
0
|
0
|
0
|
-170.86
|
-282.33
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-187.28
|
-223.06
|
0
|
| Total Other Income/Expenses Net |
-$822,924.00
|
$224,588.00
|
-$3.38 M
|
$596,652.00
|
-$2.29 M
|
-$2,234.00
|
| Income Before Tax |
-$10.88 M
|
-$21.27 M
|
-$37.57 M
|
-$13.45 M
|
-$9.16 M
|
-$2,234.00
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-179.32
|
-297.66
|
0
|
| Income Tax Expense |
-$1.06 M
|
$0.00
|
$3.39 M
|
$972,919.00
|
-$2.15 M
|
$0.00
|
| Net Income |
-$9.81 M
|
-$21.27 M
|
-$40.97 M
|
-$14.42 M
|
-$7.01 M
|
-$2,234.00
|
| Net Income Ratio |
0
|
0
|
0
|
-192.3
|
-227.87
|
0
|
| EPS |
-5.1 |
-0.83 |
-2.87 |
-1.32 |
-0.75 |
-0.0002 |
| EPS Diluted |
-5.1 |
-0.83 |
-2.87 |
-1.32 |
-0.75 |
-0.0002 |
| Weighted Average Shares Out |
$1.92 M
|
$25.69 M
|
$14.30 M
|
$10.91 M
|
$9.38 M
|
$10.78 M
|
| Weighted Average Shares Out Diluted |
$1.92 M
|
$25.69 M
|
$14.30 M
|
$10.91 M
|
$9.38 M
|
$10.78 M
|
| Link |
|
|
|
|
|
|
